Kura Oncology, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology therapies targeting cancer signaling pathways. The filing covers the three months ended March 31, 2017 and was filed May 15, 2017. The company had no approved products and no product-sales revenue.
- Lead program: Tipifarnib, evaluated in four Phase 2 studies for HRAS-mutant solid tumors, peripheral T-cell lymphoma, lower-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.
- KO-947: ERK inhibitor; the company commenced a Phase 1 trial in April 2017.
- KO-539: Menin-MLL inhibitor; nominated as a development candidate in December 2016 and remained in preclinical development.
- The company had 27 employees as of March 31, 2017.
Financial and Operating Metrics
| Metric | Q1 2017 | Q1 2016 | Change |
|---|---|---|---|
| Product revenue | None | None | Not applicable |
| Research and development expense | $5.5 million | $4.6 million | +$0.9 million |
| General and administrative expense | $2.1 million | $2.4 million | -$0.3 million |
| Total operating expenses | $7.7 million | $7.0 million | +$0.6 million |
| Other income, net | $0.1 million | $0.4 million | -$0.3 million |
| Net loss | $7.5 million | $6.6 million | Loss increased $0.9 million |
| Basic and diluted loss per share | $0.39 | $0.36 | Loss per share increased |
| Net cash used in operating activities | $8.6 million | $7.3 million | Use increased $1.3 million |
Research and development spending increased primarily because tipifarnib clinical development costs rose by approximately $1.0 million. KO-947 spending declined as IND-enabling activities were completed, and discovery/preclinical spending also decreased. Share-based compensation increased to $0.9 million from $0.5 million.
| Balance Sheet Metric | March 31, 2017 | December 31, 2016 |
|---|---|---|
| Cash and cash equivalents | $10.6 million | $9.7 million |
| Short-term investments | $48.5 million | $58.1 million |
| Cash, cash equivalents and short-term investments | $59.2 million | $67.8 million |
| Total assets | $61.9 million | $69.8 million |
| Long-term debt, net | $7.3 million | $7.3 million |
| Accumulated deficit | $61.4 million | $53.9 million |
Investing activities provided $9.5 million, primarily from maturities of marketable securities exceeding purchases. Financing activities provided $5,000 from stock-option exercises. The company reported no off-balance-sheet arrangements.
Material Changes Versus the Prior Comparable Period
- Net loss increased by approximately 14% to $7.5 million, driven primarily by higher research and development spending and interest expense.
- Research and development expense increased approximately 19%, reflecting greater tipifarnib clinical-trial activity and higher internal development costs.
- General and administrative expense declined approximately 11%, primarily because of lower professional expenses.
- Interest expense increased by approximately $0.2 million because of the term loan entered into in April 2016.
- Cash, cash equivalents and short-term investments declined by approximately $8.6 million from year-end 2016, largely reflecting operating cash use and investment maturities and purchases.
- The company commenced a Phase 1 clinical trial of KO-947 in April 2017.
- In January 2017, Kura established a $25.0 million at-the-market equity facility. As of May 12, 2017, it had sold 14,300 shares under the facility.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash, cash equivalents and short-term investments to fund current operations into the second half of 2018, but stated that significant additional financing would be required to continue development programs.
- Kura may seek additional equity or debt financing, collaborations, strategic partnerships or licensing arrangements. Additional financing may be unavailable or could dilute shareholders, impose restrictive covenants or require the company to relinquish valuable rights.
- The company had borrowed $7.5 million under a facility providing for up to $20.0 million of term loans. The additional $12.5 million Term B Loan was made available for drawdown between August 1 and October 31, 2017 under a May 2017 amendment, subject to the facility terms.
- The term loan carried an interest rate of 8.25% at March 31, 2017, matured November 1, 2020, and was interest-only through May 1, 2018, followed by principal amortization. The debt was secured by substantially all assets other than intellectual property.
- Management reported compliance with material debt covenants and no material adverse change as of March 31, 2017.
- Enrollment in the HRAS-mutant head-and-neck cancer Phase 2 trial was slower than anticipated. The company attributed this partly to increased use of immuno-oncology therapies and limited routine genetic screening, and was expanding sites and using third-party laboratories to facilitate screening.
- Clinical development remains subject to substantial risks, including failure to demonstrate safety or efficacy, enrollment delays, regulatory setbacks, manufacturing or supply problems, dependence on third parties, companion-diagnostic development, intellectual-property challenges and competition.
- Tipifarnib’s U.S. and European composition-of-matter patents expired in 2016, increasing reliance on other patents and potential regulatory exclusivity.
- The filing reported no material legal proceedings and stated that disclosure controls and procedures were effective at the end of the quarter.
Most Important Facts to Verify
- Whether cash resources and available debt capacity are sufficient to fund operations through the projected second half of 2018.
- Progress, enrollment rates and interim results for the four Phase 2 tipifarnib trials, particularly the HRAS-mutant head-and-neck cancer study.
- Safety, dose-escalation and efficacy developments in the KO-947 Phase 1 trial.
- Future use of the $25.0 million ATM facility and any additional equity or debt financing, including dilution and financing terms.
- Whether the company draws the additional Term B Loan and its resulting interest, warrant and unused-fee obligations.
- Regulatory and intellectual-property protection available for tipifarnib following expiration of composition-of-matter patents.
- Development status of companion diagnostics and the company’s ability to identify genetically defined patient populations.